Medline prices secondary offering at $41 per share

Medline Inc. (NASDAQ: MDLN) announced the pricing of a secondary offering of 75 million shares of Class A common stock at $41.00 per share. The shares are being sold by stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a subsidiary of the Abu Dhabi Investment Authority.

The selling stockholders granted underwriters a 30-day option to purchase up to an additional 11.25 million shares. The offering is expected to close on March 10, 2026, subject to customary closing conditions.

Medline will not sell any shares in the offering and will not receive proceeds from the sale, according to the company's statement.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are serving as global coordinators and joint bookrunning managers for the transaction. Additional bookrunning managers include Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair.

The Northfield, Illinois-based company describes itself as a provider of medical-surgical products and supply chain solutions serving healthcare providers. Medline employs more than 45,000 people worldwide and operates in more than 100 countries.

A registration statement relating to the securities was filed with and declared effective by the Securities and Exchange Commission.

You May Also Be Interested In

• Rithm Property Trust launches public stock offering
• Mesoblast reaches 300-patient enrollment in back pain Phase 3 trial
• Haoxi Health closes $4M direct offering via Univest Securities